What happened with KNSA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Kiniksa Pharmaceuticals International, plc sells ARCALYST to treat recurrent pericarditis—inflammation of the sac around the heart that returns after treatment—and other approved conditions in the United States. ARCALYST is its only commercial product and supplies substantially all revenue. Specialty pharmacies buy and distribute the drug, handle prescriptions and collect payer payments. Insurers and government health programs help fund treatment, so sales depend on prescribing, patient access and reimbursement. Kiniksa shares profits with Regeneron after specified manufacturing and commercialization costs are deducted.
The business also depends on Regeneron for supply: it is currently the sole manufacturer of ARCALYST’s drug substance. Kiniksa is transferring that manufacturing process to Samsung, but the transfer is not complete, and FDA approval is required before it can sell drug made at Samsung’s facility. Maintaining supply during the changeover depends on securing enough stock from Regeneron or extending its manufacturing arrangement. Kiniksa can market the drug only for approved uses; broader commercialization requires the relevant local approvals.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Kiniksa’s results depend chiefly on U.S. ARCALYST uptake and supply, with Samsung taking over drug-substance manufacturing and Genentech and Huadong offering additional licensing opportunities.
Kiniksa depends on Regeneron for the rights to ARCALYST and currently all its supply, paying Regeneron for the medicine it sells in the United States and sharing half its sales profits and third-party licensing proceeds. Watch ARCALYST supply and the manufacturing handover to Samsung: this is Kiniksa’s only commercial product.
Novartis competes with Kiniksa for CAPS patients: its Ilaris and Kiniksa’s ARCALYST both target IL-1. That overlap concerns CAPS treatment, while recurrent pericarditis remains Kiniksa’s principal commercial opportunity.
Kiniksa Pharmaceuticals International, plc earningsThis company
Kiniksa gets nearly all its product revenue from U.S. ARCALYST sales, and this report shows whether patient growth is still lifting sales and how much revenue remains after discounts and rebates.
Read patient growth alongside net product revenue after discounts, rebates and other deductions. If both rise, more treatment demand is translating into sales; if patients increase but net revenue lags, coverage terms or sales deductions are squeezing the revenue Kiniksa retains per patient.
Regeneron Pharmaceuticals Inc earningsREGN
Regeneron’s report can show how ARCALYST supply and the manufacturing transfer to Samsung are progressing; Kiniksa relies on that supply to treat patients and earn product revenue.
Watch whether Regeneron continues producing ARCALYST and whether the transfer to Samsung advances. Steady supply and progress on the transfer would support Kiniksa’s ability to keep treating patients and selling the drug; disruption or delay would put patient supply and Kiniksa’s sales at risk.
